Literature DB >> 11423879

Quality of life in atopic dermatitis.

A Y Finlay1.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11423879     DOI： 10.1067/mjd.2001.117010

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  17 in total

1.  The effect of TJ-15 plus TJ-17 on atopic dermatitis: a pilot study based on the principle of pattern identification.

Authors:  In-Hwa Choi; Sehyun Kim; YoungChul Kim; Younghee Yun
Journal:  J Altern Complement Med       Date:  2012-06       Impact factor: 2.579

Review 2.  The economics of topical immunomodulators for the treatment of atopic dermatitis.

Authors:  William Abramovits; Mark Boguniewicz; Amy S Paller; Diane L Whitaker-Worth; Mary M Prendergast; Michael Tokar; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD).

Authors:  Stephen P McKenna; Diane Whalley; Abigail L Dewar; Ruud A M Erdman; Thomas Kohlmann; Mauro Niero; Eva Baró; Sharon A Cook; Beatrice Crickx; Feride Frech; Daniel van Assche
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

Review 4.  Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.

Authors:  Keri Wellington; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids.

Authors:  Roman Schiffner; Julia Schiffner-Rohe; Michael Landthaler; Wilhelm Stolz
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  [Significance of atopic dermatitis in outpatient medical care. Analysis of health care data from Saxony].

Authors:  J Schmitt; N M Schmitt; W Kirch; M Meurer
Journal:  Hautarzt       Date:  2009-04       Impact factor: 0.751

7.  Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice.

Authors:  K Kasutani; E Fujii; S Ohyama; H Adachi; M Hasegawa; H Kitamura; N Yamashita
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

8.  Measurement properties of three assessments of burden used in atopic dermatitis in adults.

Authors:  K R Patel; V Singam; P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; R Kantor; D Y Hsu; J I Silverberg
Journal:  Br J Dermatol       Date:  2018-11-12       Impact factor: 9.302

9.  Quality of life measures in Italian children with atopic dermatitis and their families.

Authors:  Fiorella Monti; Francesca Agostini; Francesca Gobbi; Erica Neri; Sandra Schianchi; Fabio Arcangeli
Journal:  Ital J Pediatr       Date:  2011-12-22       Impact factor: 2.638

Review 10.  Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics.

Authors:  Yasaman Mansouri; Emma Guttman-Yassky
Journal:  J Clin Med       Date:  2015-04-29       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.